000143280 001__ 143280
000143280 005__ 20240229112546.0
000143280 0247_ $$2doi$$a10.1080/15592294.2019.1595998
000143280 0247_ $$2pmid$$apmid:30931802
000143280 0247_ $$2ISSN$$a1559-2294
000143280 0247_ $$2ISSN$$a1559-2308
000143280 037__ $$aDKFZ-2019-00878
000143280 041__ $$aeng
000143280 082__ $$a610
000143280 1001_ $$0P:(DE-He78)bc9ae72f1f27696587eeb1c81e48fb69$$aNeumeyer, Sonja Maria$$b0$$eFirst author$$udkfz
000143280 245__ $$aGenome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.
000143280 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2019
000143280 3367_ $$2DRIVER$$aarticle
000143280 3367_ $$2DataCite$$aOutput Types/Journal article
000143280 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1580298450_6877
000143280 3367_ $$2BibTeX$$aARTICLE
000143280 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143280 3367_ $$00$$2EndNote$$aJournal Article
000143280 520__ $$aInvolvement of sex hormones in colorectal cancer (CRC) development has been linked to oestrogen receptor β (ERβ). Expression of ERβ is found reduced in tumour tissue and inversely related to mortality. However, mechanisms are not well understood. Our study aimed to detect differentially methylated genes associated with ERβ expression, which could point to mechanisms by which ERβ could influence risk and prognosis of CRC. Epigenome-wide DNA methylation profiling was performed using Illumina HumanMethylation450k BeadChip arrays in two independent tumour sample sets of CRC patients recruited in 2003-2010 by the German DACHS study (discovery cohort n = 917, replication cohort n = 907). ERβ expression was measured using immunohistochemistry and scored as negative, moderate and high. Differentially methylated CpG sites and genomic regions were determined using limma in the R-package RnBeads. For the comparison of tumours with moderate/high ERβ versus negative expression, differentially methylated CpG sites were identified but not confirmed by replication. Comparing tumours of high with tumours of negative ERβ expression revealed 2,904 differentially methylated CpG sites of which 403 were replicated (FDR adjusted p-value<0.05). Replicated CpGs were annotated to genes such as CD36, HK1 or LRP5. A survival analysis indicates that 30 of the replicated CpGs are also associated with overall survival (FDR-adjusted p-value<0.05). The regional analysis identified 60 differentially methylated promotor regions. The epigenome-wide analysis identified both novel genes as well as genes already implicated in CRC. Follow-up mechanistic studies to better understand the regulatory role of ERβ could inform potential targets for improving treatment or prevention of CRC.
000143280 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143280 588__ $$aDataset connected to CrossRef, PubMed,
000143280 7001_ $$0P:(DE-He78)37610ef78c733753f0836ce0e41b9fda$$aPopanda, Odilia$$b1$$udkfz
000143280 7001_ $$0P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aEdelmann, Dominic$$b2$$udkfz
000143280 7001_ $$0P:(DE-He78)7ca7eafba864e5c3ebb7598149380452$$aButterbach, Katja$$b3$$udkfz
000143280 7001_ $$aToth, Csaba$$b4
000143280 7001_ $$aRoth, Wilfried$$b5
000143280 7001_ $$aBläker, Hendrik$$b6
000143280 7001_ $$0P:(DE-He78)64ae432b27ff7349ba1cee8a916932a1$$aJiang, Ruijingfang$$b7$$udkfz
000143280 7001_ $$aHerpel, Esther$$b8
000143280 7001_ $$0P:(DE-He78)cf75137db0fa4e2da0922b14b9256b3c$$aJäkel, Cornelia$$b9$$udkfz
000143280 7001_ $$0P:(DE-He78)141ce740f5d881812d2675147b72ecaf$$aSchmezer, Peter$$b10$$udkfz
000143280 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b11$$udkfz
000143280 7001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b12$$udkfz
000143280 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b13$$udkfz
000143280 7001_ $$0P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aBurwinkel, Barbara$$b14$$udkfz
000143280 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b15$$udkfz
000143280 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b16$$udkfz
000143280 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b17$$eLast author$$udkfz
000143280 773__ $$0PERI:(DE-600)2248598-3$$a10.1080/15592294.2019.1595998$$gp. 1 - 17$$n5$$p477-493$$tEpigenetics$$v14$$x1559-2308$$y2019
000143280 909CO $$ooai:inrepo02.dkfz.de:143280$$pVDB
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bc9ae72f1f27696587eeb1c81e48fb69$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)37610ef78c733753f0836ce0e41b9fda$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ca7eafba864e5c3ebb7598149380452$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)64ae432b27ff7349ba1cee8a916932a1$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cf75137db0fa4e2da0922b14b9256b3c$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)141ce740f5d881812d2675147b72ecaf$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000143280 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000143280 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143280 9141_ $$y2019
000143280 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPIGENETICS-US : 2017
000143280 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143280 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143280 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143280 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143280 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143280 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143280 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143280 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143280 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143280 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000143280 9201_ $$0I:(DE-He78)B370-20160331$$kB370$$lEpigenomik$$x1
000143280 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x2
000143280 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x3
000143280 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000143280 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x5
000143280 980__ $$ajournal
000143280 980__ $$aVDB
000143280 980__ $$aI:(DE-He78)C020-20160331
000143280 980__ $$aI:(DE-He78)B370-20160331
000143280 980__ $$aI:(DE-He78)C060-20160331
000143280 980__ $$aI:(DE-He78)C070-20160331
000143280 980__ $$aI:(DE-He78)L101-20160331
000143280 980__ $$aI:(DE-He78)L501-20160331
000143280 980__ $$aUNRESTRICTED